Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 59.9% in May

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTGet Rating) saw a significant decline in short interest in May. As of May 15th, there was short interest totalling 54,500 shares, a decline of 59.9% from the April 30th total of 136,000 shares. Based on an average daily volume of 3,570,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.8% of the shares of the stock are sold short.

LIXT traded down $0.01 during trading on Friday, reaching $0.76. The company had a trading volume of 2,706 shares, compared to its average volume of 3,650,878. The business’s fifty day moving average price is $1.20 and its 200 day moving average price is $1.46. Lixte Biotechnology has a 12 month low of $0.72 and a 12 month high of $4.95.

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. increased its stake in Lixte Biotechnology by 191.9% in the 3rd quarter. BlackRock Inc. now owns 13,425 shares of the company’s stock worth $28,000 after acquiring an additional 8,826 shares during the last quarter. Morgan Stanley bought a new position in Lixte Biotechnology during the 1st quarter valued at about $69,000. EP Wealth Advisors LLC purchased a new stake in Lixte Biotechnology in the 1st quarter worth approximately $31,000. Finally, Geode Capital Management LLC purchased a new stake in Lixte Biotechnology during the 3rd quarter valued at approximately $78,000. 8.82% of the stock is currently owned by institutional investors.

Lixte Biotechnology Company Profile (Get Rating)

Lixte Biotechnology Holdings, Inc operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.

Featured Stories

Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with's FREE daily email newsletter.